Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results
Jörge E. Cortes, D Réa, Michael J. Mauro, Andreas Hochhaus et autres
0 citationsLeukemia
Matthias Hoch
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
110Publications signalées
1371Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Chronic Myeloid Leukemia TreatmentsEstrogen and related hormone effectsChronic Lymphocytic Leukemia ResearchSphingolipid Metabolism and SignalingLung Cancer Treatments and Mutations
Publications récentes
ASC4Kids-2: Asciminib in pediatric chronic myeloid leukemia with or without T315I.
Nobuko Hijiya, Andrew E. Place, Cornelia Garnitz, Ana Paula Cardoso et autres
0 citationsJournal of Clinical Oncology
Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants
Matthias Hoch, Amanda Taylor, Felix Huth, Seshulatha Jamalapuram et autres
0 citationsClinical Pharmacokinetics
Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase
Sherwin K. B. Sy, Deok Yong Yoon, Yiqun Yang, Christelle Darstein et autres
0 citationsClinical Pharmacokinetics
Asciminib pediatric formulation shows a tolerable safety profile in pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP): Second interim analysis from the ASC4KIDS study
Jessica A. Pollard, Hiroyuki Shimada, S. S. Kapoor, Matthias Hoch et autres
0 citationsBlood
High rates of deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) who have not achieved dmr after ≥1 year of prior imatinib (IMA) in the asciminib (ASC) monotherapy arm of the Phase 2 ASC4MORE study
Jörge E. Cortes, Giuseppe Saglio, Jan Geißler, Jiří Mayer et autres
0 citationsBlood
Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram et autres
1 citationClinical Pharmacology in Drug Development
Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib
Ioannis Loisios-Konstantinidis, Felix Huth, Matthias Hoch, Heidi J. Einolf
6 citationsPharmaceutics
Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase
Sherwin K. B. Sy, Yiqun Yang, Christelle Darstein, Deok Yong Yoon et autres
2 citationsCancer Chemotherapy and Pharmacology
New pediatric formulation of asciminib in children with chronic myeloid leukemia in chronic phase: Second interim analysis of pharmacokinetics and safety from the ASC4Kids study.
Nobuko Hijiya, Jessica A. Pollard, Hiroyuki Shimada, S. S. Kapoor et autres
0 citationsJournal of Clinical Oncology
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results
Andreas Hochhaus, Dong‐Wook Kim, Jörge E. Cortes, Koji Sasaki et autres
13 citationsLeukemia
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results
Jörge E. Cortes, Fabian Lang, Delphine Réa, Andreas Hochhaus et autres
15 citationsLeukemia
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.